Hepatic Disorders and COVID-19: From Pathophysiology to Treatment Strategy

Area of Science:

• Hepatology
• Virology
• Infectious Diseases

Background:

• The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has highlighted the vulnerability of multiple organs, including the liver.
• Liver disease is a significant risk factor for mortality in coronavirus disease 2019 (COVID-19) patients.
• SARS-CoV-2 infection can cause liver injury, particularly in severe cases, and is exacerbated by certain medications and pre-existing conditions like cirrhosis.

Purpose of the Study:

• To review the hepatic impairment caused by SARS-CoV-2 infection.
• To assess the impact of drugs used during the COVID-19 pandemic on mortality in liver disease patients.
• To explore potential preventive measures for SARS-CoV-2 infection in individuals with liver conditions.

Main Methods:

• Literature review of studies on SARS-CoV-2 and liver disease.
• Analysis of clinical data regarding COVID-19 outcomes in patients with hepatic conditions.
• Examination of the role of antiviral and immunosuppressive therapies in SARS-CoV-2-induced liver injury.

Main Results:

• Liver damage is prevalent in COVID-19 patients, correlating with disease severity.
• Pre-existing liver diseases, including cirrhosis, increase COVID-19 mortality risk.
• Certain medications used during the pandemic may contribute to SARS-CoV-2-related liver injury.

Conclusions:

• Patients with liver disease require careful management during the COVID-19 pandemic due to increased mortality risks.
• Understanding drug interactions and disease progression is crucial for developing effective preventive strategies.
• Further research is needed to optimize care and reduce mortality in this vulnerable population.